A
Ashok Dongre
Researcher at Bristol-Myers Squibb
Publications - 47
Citations - 3233
Ashok Dongre is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Tandem mass spectrometry & Signal transduction. The author has an hindex of 21, co-authored 45 publications receiving 3026 citations. Previous affiliations of Ashok Dongre include Virginia Commonwealth University & University of Washington.
Papers
More filters
Journal ArticleDOI
Influence of Peptide Composition, Gas-Phase Basicity, and Chemical Modification on Fragmentation Efficiency: Evidence for the Mobile Proton Model
TL;DR: The relative positions of the ESI/SID fragmentation efficiency curves depend on several parameters which include peptide composition (e.g., presence/absence of a basic amino acid residue) and peptide size.
Journal ArticleDOI
Surface-induced dissociation: an effective tool to probe structure, energetics and fragmentation mechanisms of protonated peptides.
TL;DR: The observed trends support the essential role of the mobile proton model in understanding peptide fragmentation by low-energy tandem mass spectrometry.
Journal ArticleDOI
Fragmentation of protonated peptides: surface-induced dissociation in conjunction with a quantum mechanical approach.
TL;DR: A theoretical approach based on MNDO bond order calculations is suggested for the description of peptide fragmentation and explains the easy cleavage of the amide bond, charge-remote backbone and side-chain cleavages, and the influence of intramolecular H-bonding.
Journal ArticleDOI
Biomarker discovery in urine by proteomics.
TL;DR: One acute phase reactant, orosomucoid, was readily observed in all three experiments to dramatically increase in abundance, thereby supporting the hypothesis that it would be possible to isolate an adequate amount of protein from a patient, having normal renal function, to identify biological markers of a particular disease state using a variety of proteomics techniques.
Journal ArticleDOI
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Fei Huang,Ann Greer,Warren Hurlburt,Xia Han,Rameh Hafezi,Gayle M. Wittenberg,Gayle M. Wittenberg,Karen A. Reeves,Jiwen Chen,Douglas Michael Robinson,Aixin Li,Francis Y. Lee,Marco M. Gottardis,Edwin A. Clark,Lee J. Helman,Ricardo M. Attar,Ashok Dongre,Joan M. Carboni +17 more
TL;DR: A strategy for testing combinations of IGF-IR inhibitors with other targeted therapies in clinical studies to achieve improved patient outcomes is provided and further exploration of mechanisms for intrinsic and acquired drug resistance by these preclinical studies may lead to more rationally designed drugs that target multiple pathways for enhanced antitumor efficacy.